DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 1,776 filers reported holding DANAHER CORPORATION in Q4 2020. The put-call ratio across all filers is 0.97 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2024 | $206,269 | -63.3% | 826 | -62.9% | 0.08% | -69.4% |
| Q1 2023 | $561,797 | +94798.1% | 2,229 | 0.0% | 0.27% | -15.0% |
| Q4 2022 | $592 | -99.9% | 2,229 | -1.9% | 0.32% | -28.2% |
| Q3 2022 | $587,000 | +6.9% | 2,273 | +4.8% | 0.44% | +11.3% |
| Q2 2022 | $549,000 | -13.4% | 2,169 | +0.4% | 0.40% | -6.8% |
| Q1 2022 | $634,000 | -10.8% | 2,160 | 0.0% | 0.43% | -11.0% |
| Q4 2021 | $711,000 | +8.1% | 2,160 | 0.0% | 0.48% | +0.6% |
| Q3 2021 | $658,000 | +13.4% | 2,160 | 0.0% | 0.48% | +29.5% |
| Q2 2021 | $580,000 | +16.9% | 2,160 | -2.0% | 0.37% | +14.2% |
| Q1 2021 | $496,000 | +3.3% | 2,205 | +2.1% | 0.32% | -4.4% |
| Q4 2020 | $480,000 | +3.2% | 2,160 | 0.0% | 0.34% | +9.0% |
| Q3 2020 | $465,000 | +21.7% | 2,160 | 0.0% | 0.31% | +14.8% |
| Q2 2020 | $382,000 | +27.8% | 2,160 | 0.0% | 0.27% | +12.5% |
| Q1 2020 | $299,000 | +864.5% | 2,160 | +895.4% | 0.24% | +1042.9% |
| Q2 2019 | $31,000 | – | 217 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ace Management Global Ltd. | 168,488 | $42,096,727 | 12.36% |
| Zeno Equity Partners LLP | 182,612 | $45,660,122 | 12.15% |
| Defender Capital, LLC. | 135,187 | $33,776,567 | 11.54% |
| Bancreek Capital Management, LP | 56,267 | $14,058,310 | 10.98% |
| ARTHUR M. COHEN & ASSOCIATES, LLC | 214,830 | $53,664,407 | 9.84% |
| CADEN CAPITAL PARTNERS, LP | 104,501 | $26,109,575 | 9.44% |
| Dorsey Asset Management | 306,420 | $76,559,037 | 9.12% |
| Consulta Ltd | 500,000 | $124,925,000 | 8.51% |
| BOONE CAPITAL MANAGEMENT LLC | 106,360 | $26,574,046 | 6.93% |
| Manchester Global Management (UK) Ltd | 150,688 | $37,649,397 | 6.62% |